Literature DB >> 327012

Trypanosoma cruzi: modification of macrophage function during infection.

N Nogueira, S Gordon, Z Cohn.   

Abstract

Infection of mice with Trypanosoma cruzi and subsequent intraperitoneal challenge with heat-killed trypanosomes elicits peritoneal macrophages which display in vitro microbicidal activity against trypomastigotes of T. cruzi. These cells also display other activated properties including rapid spreading, intense membrane activity, secretion of high levels of plasminogen activator, and ingestion mediated by the C3 receptor. An intravenous infection with BCG, followed by an intraperitoneal challenge with mycobacterial antigens brings about macrophages with similar properties. These criteria of macrophage activation were compared in normal and BCG- or T. cruzi-immune mice, with or without an intraperitoneal challenge with specific or unrelated antigens. Trypanocidal activity is displayed by both BCG- and T. cruzi-immune macrophages after intraperitoneal challenge with either antigen. Resident-immune macrophages from both T. cruzi- and BCG-infected mice show a trypanostatic, rather than trypanocidal activity. Macrophages from noninfected mice, challenged with the same antigens, show neither trypanostatic nor trypanocidal activity. Increased secretion of plasminogen activator shows a definite immunological specificity. Challenge with the specific antigen induces the appearance of macrophages secreting high levels of plasminogen activator, while unrelated antigens induce much smaller levels. Noninfected mice challenged with the same antigens do not display any enchancement in secretion. In contrast, increased spreading and phagocytosis mediated by the complement receptor are also displayed by cells from noninfected mice challenged with any of the agents tested.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 327012      PMCID: PMC2180730          DOI: 10.1084/jem.146.1.157

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  In vitro nonimmunologic destruction of cells with abnormal growth characteristics by adjuvant activated macrophages.

Authors:  J B Hibbs; L H Lambert; J S Remington
Journal:  Proc Soc Exp Biol Med       Date:  1972-03

3.  Humoral and cellular responses to Trypanosoma cruzi infection.

Authors:  J F Yanovsky; E Albado
Journal:  J Immunol       Date:  1972-11       Impact factor: 5.422

4.  Lymphocyte transformation in Chagas disease.

Authors:  E I Tschudi; D F Anziano; A P Dalmasso
Journal:  Infect Immun       Date:  1972-12       Impact factor: 3.441

5.  The induction of macrophage spreading: role of coagulation factors and the complement system.

Authors:  C Bianco; A Eden; Z A Cohn
Journal:  J Exp Med       Date:  1976-12-01       Impact factor: 14.307

6.  Studies on the selective lysis and purification of Trypanosoma cruzi.

Authors:  N Nogueira; C Bianco; Z Cohn
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

7.  Elastase secretion by stimulated macrophages. Characterization and regulation.

Authors:  Z Werb; S Gordon
Journal:  J Exp Med       Date:  1975-08-01       Impact factor: 14.307

8.  THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCE.

Authors:  G B MACKANESS
Journal:  J Exp Med       Date:  1964-07-01       Impact factor: 14.307

9.  Requirement of thymus (T) lymphocytes for resistance to listeriosis.

Authors:  F C Lane; E R Unanue
Journal:  J Exp Med       Date:  1972-05-01       Impact factor: 14.307

10.  THE DIFFERENTIATION OF MONONUCLEAR PHAGOCYTES. MORPHOLOGY, CYTOCHEMISTRY, AND BIOCHEMISTRY.

Authors:  Z A COHN; B BENSON
Journal:  J Exp Med       Date:  1965-01-01       Impact factor: 14.307

View more
  28 in total

1.  Modulation of plasminogen activator secretion by activated macrophages: influence of serum factors and correlation with tumoricidal potential.

Authors:  H A Chapman; Z Vavrin; J B Hibbs
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

Review 2.  Macrophage proteases and rheumatic diseases: regulation of plasminogen activator by thymus-derived lymphocytes.

Authors:  S Gordon; W Newman; B Bloom
Journal:  Agents Actions       Date:  1978-01

3.  Induction of the acute-phase protein serum amyloid P in experimental Chagas' disease.

Authors:  J Scharfstein; M A Barcinski; L L Leon
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

4.  Dissociation of bactericidal activity from other functions of activated macrophages in exudates induced by thioglycolate medium.

Authors:  G L Spitalny
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

5.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

6.  Bacille Calmette-Guérin infection in the mouse. Regulation of macrophage plasminogen activator by T lymphocytes and specific antigen.

Authors:  S Gordon; Z A Cohn
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

7.  Fate of Listeria monocytogenes in resident and activated macrophages.

Authors:  L Harrington-Fowler; P M Henson; M S Wilder
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

8.  Fate of Listeria monocytogenes in murine peritoneal macrophage subpopulations.

Authors:  L Harrington-Fowler; M S Wilder
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

9.  Specific glycoprotein antigens on the surface of insect and mammalian stages of Trypanosoma cruzi.

Authors:  N Nogueira; J Unkeless; Z Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

10.  Activated human monocytes inhibit the intracellular multiplication of Legionnaires' disease bacteria.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.